Showing papers in "Clinical and Translational Radiation Oncology in 2019"

TL;DR: The Elekta Unity MR-linac adaptive radiotherapy concept is explained and different methods for dose re-calculation and optimization are discussed, with full online re-planning being the most robust adaptive planning method for the Unity.

TL;DR: The 0.35 T MR-Linac combines a 6MV linac with onboard MR imaging that provides superior soft-tissue contrast compared to X-ray IGRT and allows a fully integrated on-table adaptive workflow.

TL;DR: Hypoxia-activated prodrugs have yielded promising results up to phase II trials, but implementation in the clinic has not been successful and phase III clinical trials lack patient stratification based on tumor hypoxia status.

TL;DR: An MR-only treatment planning could improve the spatial accuracy of radiotherapy and the benefit compared to a mixed MR-CT workflow will vary between patient groups.

TL;DR: Proposed correction method suppresses the non-tumor related variation in radiomics and the clinical relevance was shown using a 221 lung cancer patient cohort.

TL;DR: In conclusion, Integrated Low-field MR provides better anatomical visualization than CBCT or MVCT and appears a feasible option in rectal cancer treatment offering potential benefits.

TL;DR: Telehealth serviced a range of ages, cancer diagnoses and treatment intents, and patients reported an overall high level of satisfaction with telehealth consultation.

TL;DR: Chatbots are artificial intelligence–driven programs that interact with people that can be used for screening, treatment adherence and follow-up and deployed as text-based services on a website or mobile applications.

TL;DR: Development and adaptation of the existing radiotherapy multidisciplinary workforce is essential to enable an efficient and effective MR-guided radiotherapy workflow, relevant due to the increasing availability of MR- guided radiotherapy.

TL;DR: Hemostatic radiotherapy is highly effective (89% bleeding control), but only 24% of the patients presenting with oncologic bleeding were alive after 1 year.

TL;DR: Radiotherapy with ablative doses can overcome RCC’s radioresistance and MR-guided SBRT for localized RCC may be used for adaptive planning in the future.

TL;DR: High local control rates even for LAPC with biological dose-escalation using SBRT using MR-guided adaptive SBRTs and high-dose constraints of adjacent OARs will remain the limiting factor.

TL;DR: The GI-GPA is useful in treatment selection and stratification of clinical trials and will better estimate survival within this cohort of GI cancer patients.

TL;DR: Cardiovascular risk factors predict for cardiac death after breast radiotherapy and studies are needed to evaluate heart and LAD constraints in the CT-planning era.

TL;DR: In this paper, the role of radiation in ETMR was reviewed and the initial results with proton therapy were described, showing that ETMR patients with abundant neuropil and true rosettes (ETANTR), medulloepithelioma (MEP), and ependymoblastoma (EPL) were treated with Proton therapy.

TL;DR: Current brachial plexus dose constraints are based on limited retrospective data andMeta-analysis generated model estimates a 1.11 RR increase in RIBP per 1 Gy bpDmax, which is required to further refine predictive model.

TL;DR: Dosimetric parameters for the heart and lung are associated with overall survival in esophageal cancer patients and relationship with clinical outcomes are predictive for surgical and non-surgical patients.

TL;DR: Department of Radiation Oncology, Eberhard Karls Universität Tübingen, Tüyingen, Germany German Cancer Consortium (DKTK) and Fondazione Policlinico Universitario ‘‘A. Gemelli’’ are sponsors of this research.

TL;DR: “Seeing and Zapping” metastatic lymph nodes comes within reach for MRI-guided SBRT, and a 3 mm isotropic GTV-PTV margin was adequate.

TL;DR: In some cases considerable GTV delineation variability was observed at the cranial-caudal border, however its impact on observer variation was limited.

TL;DR: Re-IRradiation using proton therapy for recurrent breast cancer has excellent local control and there is minimal increase in the late toxicity due to re-irradiation Using proton beam therapy.

TL;DR: MRgRT combining with daily plan adaptation indicates adjusting existing workflows and role and responsibilities of RTT will expand with growing clinical experience.

TL;DR: MRI-CT deformable image registration was not superior to rigid registration and registration quality was superior in muscle and gland compared to bone and vessel.

TL;DR: External beam radiotherapy provides good symptom control for esophageal cancer and a higher dose schedule is related to a longer time to second intervention.

TL;DR: Treatment for squamous cell carcinoma of the bladder is extrapolated from urothelial carcinoma, and patients with SqCC do worse than counterparts with uroclinical carcinoma following chemoRT.

TL;DR: Tumour volume, p16 status and N stage could be validated regarding LRC and OS and addition of cancer stem cell markers can further improve the baseline model.

TL;DR: The prone approach appeared to be more favorable with respect to the chest wall, and ipsilateral lung dose compared to the supine position, and the MRI-linac and clinical plans were comparable, with minor absolute dosimetric differences.

TL;DR: Issues of MRI that are relevant for radiation oncologists are addressed and MR images must be made in treatment position with the standard positioning devices.

TL;DR: The RILA assay is the leading candidate biomarker for radiotherapy toxicity and work to standardise its use across multiple centres is described to establish the basis for implementing the assay clinically.

TL;DR: Patients with locally advanced EGFR+ NSCLC patients have a high likelihood of brain metastasis, independent of survival duration, and surveillance MRI may allow early identification and treatment ofbrain metastasis.